The Centers for Disease Control and Prevention yesterday issued a health advisory warning of an uptick over the last year in meningococcal disease in which isolates show the gene associated with penicillin resistance and mutations associated with ciprofloxacin resistance.

CDC said the majority of cases were in Hispanic individuals.

The agency recommends the following for providers and clinicians:

  • Health care providers should perform antimicrobial susceptibility testing to determine susceptibility of all meningococcal isolates to penicillin before changing from empirical treatment with cefotaxime or ceftriaxone to penicillin or ampicillin.
  • In states that have experienced meningococcal disease cases caused by ciprofloxacin-resistant strains within the past 1–2 years, clinicians and public health staff should consider AST on meningococcal isolates to inform prophylaxis decisions. AST should not delay the initiation of prophylaxis with ciprofloxacin, rifampin or ceftriaxone.

Related News Articles

Headline
The deadline for health delivery organizations to apply for the AHA’s 2026 Foster G. McGaw Prize is 1 p.m. ET May 6. The award honors organizations that…
Headline
A study published March 31 by the National Institutes of Health found that adults living in rural areas have worse cardiovascular health than those in urban…
Headline
Cigarette smoking by adults has dropped to its lowest level in 60 years, the Centers for Disease Control and Prevention reported today. Despite that, tobacco…
Headline
In this conversation, Mindy Estes, M.D., former CEO of Saint Luke's Health System and former AHA board chair, and Roxanna Gapstur, R.N., CEO of WellSpan Health…
Headline
A case study by the AHA's Community Health Improvement network explains how Children’s Mercy Kansas City created a new model to coordinate its community…
Chairperson's File
Trust — in one another, in our field, and in our communities — is so important to what we do. Everyone should know that our hospitals and health systems are a…